Drug Patents owned by Aerie Pharms Inc

1. Drug name - RHOPRESSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8450344 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US9096569 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10654844 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US10174017 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US8394826 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(8 years from now)

US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

CN105263494A AERIE PHARMS INC Combination Therapy
Aug, 2020

(2 years ago)

CN109528721A AERIE PHARMS INC Combination Therapy
Mar, 2034

(11 years from now)

CN109528721B AERIE PHARMS INC Combination Therapy
Mar, 2034

(11 years from now)

EP2326623A2 AERIE PHARMS INC Beta-And Gamma-Amino-Isoquinoline Amide Compounds And Substituted Benzamide Compounds
Jul, 2029

(6 years from now)

EP2326623B1 AERIE PHARMS INC Beta-And Gamma-Amino-Isoquinoline Amide Compounds And Substituted Benzamide Compounds
Jul, 2029

(6 years from now)

EP2424842B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3354643A1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3354643B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP2424842A2 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3053913A1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3053913B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP2976080A1 AERIE PHARMS INC Conjugates Of Isoquinoline Compounds And Prostaglandins
Mar, 2034

(11 years from now)

EP2976080B1 AERIE PHARMS INC Conjugates Of Isoquinoline Compounds And Prostaglandins
Mar, 2034

(11 years from now)

EP3461484B1 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

EP3461484A1 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

EP3461484B9 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021456 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds Jul, 2026

(3 years from now)

US10882840 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds Jul, 2026

(3 years from now)

US10532993 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds Jul, 2026

(3 years from now)

US11028081 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease Jan, 2030

(7 years from now)

US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure Mar, 2034

(11 years from now)

Drugs and Companies using NETARSUDIL MESYLATE ingredient

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.02% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

2. Drug name - ROCKLATAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8450344 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US9096569 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10174017 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US10654844 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US8394826 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(8 years from now)

US9993470 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

CN105263494A AERIE PHARMS INC Combination Therapy
Aug, 2020

(2 years ago)

CN109528721A AERIE PHARMS INC Combination Therapy
Mar, 2034

(11 years from now)

CN109528721B AERIE PHARMS INC Combination Therapy
Mar, 2034

(11 years from now)

EP2326623A2 AERIE PHARMS INC Beta-And Gamma-Amino-Isoquinoline Amide Compounds And Substituted Benzamide Compounds
Jul, 2029

(6 years from now)

EP2326623B1 AERIE PHARMS INC Beta-And Gamma-Amino-Isoquinoline Amide Compounds And Substituted Benzamide Compounds
Jul, 2029

(6 years from now)

EP2424842B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3354643A1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3354643B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP2424842A2 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3053913A1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3053913B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP2976080A1 AERIE PHARMS INC Conjugates Of Isoquinoline Compounds And Prostaglandins
Mar, 2034

(11 years from now)

EP2976080B1 AERIE PHARMS INC Conjugates Of Isoquinoline Compounds And Prostaglandins
Mar, 2034

(11 years from now)

EP3461484B1 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

EP3461484A1 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

EP3461484B9 AERIE PHARMS INC Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders
Mar, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10532993 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds Jul, 2026

(3 years from now)

US11021456 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds Jul, 2026

(3 years from now)

US10882840 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds Jul, 2026

(3 years from now)

US11028081 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease Jan, 2030

(7 years from now)

US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure Mar, 2034

(11 years from now)

US11197853 AERIE PHARMS INC Combination therapy Mar, 2034

(11 years from now)

Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.005%;EQ 0.02% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.